Business Context and Reporting Period
This Form 8-K Current Report, dated April 25, 2022, details a significant executive leadership transition at Quanterix Corporation (QTRX). The filing reports the implementation of a succession plan previously announced on March 1, 2022, effective April 25, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Dr. Masoud Toloue (New CEO): Annualized base salary of $550,000; annual performance bonus target of up to 100% of base salary.
- Dr. Toloue Equity Grant: Aggregate grant date fair value of $2,000,000 (70% options, 30% RSUs) vesting over four years.
- Mr. E. Kevin Hrusovsky (Executive Chairman): Annualized base salary of $400,000; bonus target of up to 100% of base salary contingent on employment through December 31, 2022.
- Mr. Hrusovsky Equity Grant: Aggregate grant date fair value of $1,400,000 (70% options, 30% RSUs) vesting over four years.
Material Changes
The primary material change is the shift in executive leadership roles effective April 25, 2022:
- Departure of CEO: E. Kevin Hrusovsky transitioned from Chief Executive Officer to Executive Chairman of the Board.
- Appointment of CEO: Masoud Toloue, Ph.D., formerly President of Quanterix and Diagnostics, was appointed Chief Executive Officer.
- Board Appointment: Dr. Toloue was appointed to the Board of Directors as a Class II director, serving until the 2022 annual meeting.
Outlook, Risks, and Contingencies
The filing outlines specific severance and equity acceleration contingencies tied to the new employment agreements:
- Dr. Toloue Severance: In the event of termination without Cause or resignation for Good Reason, he is entitled to 12 months of base salary, the annual target bonus, and acceleration of unvested Sign-On Equity Awards that would have vested during the severance period. In a Change-in-Control scenario, all unvested equity awards accelerate fully.
- Mr. Hrusovsky Severance: In the event of termination without Cause or resignation for Good Reason during his term, he receives 6 months of salary or through the remainder of the term (whichever is later), plus health benefits. If terminated within 12 months following a Sale Event, salary and benefits continue for 12 months post-termination.
- Equity Acceleration (Hrusovsky): If a Sale Event occurs prior to December 31, 2023, and Mr. Hrusovsky is terminated without Cause/Good Reason, not retained as Executive Chairman after December 31, 2022, or not re-nominated as a director by December 31, 2023, all unvested equity grants will immediately vest.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Agreements for Dr. Toloue (Exhibit 10.1) and Mr. Hrusovsky (Exhibit 10.2) to confirm specific definitions of "Cause," "Good Reason," and "Change-in-Control."
- Confirm the vesting schedule details for the $2,000,000 and $1,400,000 equity grants, specifically the 70/30 split between options and RSUs.
- Monitor the company's performance and strategic direction under the new CEO, Dr. Toloue, given his background in growing diagnostics businesses at PerkinElmer.
- Review the timeline for Mr. Hrusovsky's transition to Executive Chairman, which is set to conclude on December 31, 2022.